Arrowhead Pharmaceuticals Inc (ARWR) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Total Assets Chart for Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc (ARWR) total assets for FY2025 were USD 1.4B, a 21.5% change from FY2024. Arrowhead Pharmaceuticals Inc's total assets grew from USD 107.7K in 1997 to USD 1.4B in 2025 (1286404.3% over 28 years). Total assets compound annual growth rate: 5-year CAGR of 21.5%, 10-year CAGR of 26.5%, 20-year CAGR of 21.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$8.67B
Implied Share Price
$61.54
Enterprise Value
$8.84B
Revenue (TTM)
$669.49M
EBITDA
-$200.64M
Profit Margin
-47.79%
Trailing P/E
—
Forward P/E
111.11
Price/Book (MRQ)
20.55
Price/Sales (TTM)
12.98
EV/EBITDA
27.85
EV/Revenue
13.37
Dividend Yield
—
Book Value
$3.30
Free Cash Flow (FY2025)
$156.89M
Free Cash Flow Yield
1.81%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.